By SPC News Staff
The FDA granted a new indication to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients aged 12 years and older with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC) that has progressed after treatment with a fluoropyrimidine, oxaliplatin and irinotecan.
The approval was based on data from Study CA209142 (CheckMate 142; ClinicalTrials.gov Identifier: NCT02060188), a multicenter,